SLC15A1 and cancer: Finally, even if genetic variability for PEPT1 and PEPT2 is rather low, there is a recent report investigating the PEPT2 genetic variant rs2257212 (SLC15A2 c.1048C>T, p.L350F) as a potential predictor of actinomycin D (act D) pharmacokinetics in pediatric cancer patients [227].